Home >
International sites
Click on the name of an international website to read its description.
International
International Federation of Psoriasis Associations / IFPA
The International Federation of Psoriasis Associations (IFPA) is a non profit organization made up of psoriasis associations from around the world.
IFPA unites psoriasis associations so that their global campaign for improved medical care, greater public understanding and increased research will improve the lives of people who live with psoriasis and psoriatic arthritis and explore the challenges psoriasis presents to the international psoriasis community.
World Psoriasis Day 29 October
World Psoriasis Day 29 October. IFPA, the International Federation of Psoriasis Associations and a global consortium of patient associations from all over the world have come together and this day has officially been declared World Psoriasis Day.
Its purpose? To act as a focus for people - awareness of psoriasis and to give these people the attention and consideration they deserve.
SOLAPSO - Sociedad Latinoamericana de Psoriasis
SOLAPSO (Sociedad Latinoamericana de Psoriasis) is a new organization which invites professionals in health from Latin America, who have an special interest in Psoriasis.
Our main aims are the following:
- Encourage Psoriasis research development and medical advance in Latin America.
- Foster the academic education of medical doctors specialized in Psoriasis, by means of human resources training and research.
- Encourage Psoriasis media information through health professionals entertainment programs in Latin-American countries.
- Foster information and vocational training exchange with other international organizations.
- Generate the necessary resources to promote Psoriasis teaching, research and training of young doctors specializing in psoriasis.
- Support scientific psoriasis publications.
- Encourage interdisciplinary work.
LATINAPSO - Red Latinoamericana de Psoriasis
LATINAPSO - the Latina American Psoriasis Network gathers several psoriasis patients associations that fight to improve the quality of life of those who suffer from this disease.
Motivated against the global ignorance of psoriasis in Latin America, the patient associations of Argentina, Brazil, Chile, Colombia, Ecuador, Mexico, Panama, Puerto Rico and Venezuela have decided to come together in order to stregthen their fight for psoriasis patients’ rights.
GRAPPA - Group for Research and Assessment of Psoriasis and Psoriatic Arthritis
GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) is organized exclusively for non-profit, educational, and scientific purposes, specifically to facilitate sharing of information related to psoriasis and psoriatic arthritis, networking among different medical disciplines that see psoriasis and psoriatic arthritis patients and to enhance research, diagnosis and treatment of psoriasis and psoriatic arthritis. More than 400 rheumatologists, dermatologists and related professionals comprise the worldwide membership of GRAPPA.
International Psoriasis Council
The International Psoriasis Council (IPC) is a dermatology led, global nonprofit organization dedicated to innovation across the full spectrum of psoriasis through research, education and treatment. IPC identifies research priorities, brings international experts together and facilitates discussion to provide the best evidence based education for dermatologists and treatment for patients.
Europe
European Federation of Psoriasis Associations / EUROPSO
EUROPSO was founded in November 1988 and is a federation of psoriasis patients’ associations based in the geographic region of Europe. As an umbrella organisation operating within Europe, we have close ties to the worldwide psoriasis movements – the International Federation of Psoriasis Associations (IFPA), the United States-based National Psoriasis Foundation (NPF) and to the Nordic Psoriasis alliance (NORDPSO).
Psonet - European registry of psoriasis
Psonet is a network of independent European registries of patients suffering from psoriasis or psoriatic arthritis and being treated by systemic agents. The final aim is to improve knowledge concerning prognostic factors and clinical outcome, offering psoriatic patients the best possible treatment.
SPIN Presentation
Recent news
- 2019/08/12 Focus on...
Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis
- 2019/06/03 Focus on...
- 2019/05/21 Focus on...
- 2019/04/18 Focus on...
- 2019/04/17 Focus on...
News from the web office
- 2016/10/29
- 2016/05/26
- 2016/02/20
Events
- 2019/04/18 Focus on...
- 2018/02/21
News from medical groups
- 2018/04/18
- 2017/06/21
News from patients associations
- 2017/02/08
- 2016/05/26
Recent publications on Psoriasis and Atopic Dermatitis
on Psoriasis
Special aspects of biologics treatment in psoriasis: management in pregnancy, lactation, surgery, renal impairment, hepatitis and tuberculosis.
J Dermatolog Treat.
2019 Nov , 30, (7):668-673.
: Biologics are modern immunomodulatory drugs, whose use in the treatment of psoriasis has led to remarkable results in psoriatic patients. The administration of these agents in special population groups, such as patients with chronic infections and renal impairment, as well as perioperative, pregnant or lactating patients, has not been thoroughly addressed, mostly because these patients are excluded from clinical studies. This report is an updated systematic overview of the use of (...)
see on pubmed
JAK-inhibitors in dermatology: current evidence and future applications.
Ciechanowicz P et al.
JAK-inhibitors in dermatology: current evidence and future applications.
J Dermatolog Treat.
2019 Nov , 30, (7):648-658.
The Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway is a ubiquitous intracellular signaling network. Selective JAK-inhibitors have anti-inflammatory properties and have been approved in many countries for the treatment of rheumatoid arthritis (tofacitinib, baricitinib) and myelofibrosis or polycythemia vera (ruxolitinib). The aim of the publication was to summarize and critically analyze the efficacy and safety of JAK-inhibitors in skin diseases, such (...)
see on pubmed
Patient preferences for attributes of topical anti-psoriatic medicines.
Vasconcelos V et al.
Patient preferences for attributes of topical anti-psoriatic medicines.
J Dermatolog Treat.
2019 Nov , 30, (7):659-663.
Patient preferences should be considered when prescribing topical treatments to drive up adherence and improve clinical outcomes. The aim of this work was to identify the most important attributes of topical medicines for psoriasis treatment in the patients' view, and explore the sociodemographic and clinical determinants of these preferences. A questionnaire for the evaluation of the relevancy given to specific attributes of topical medicines used for psoriasis treatment was developed (...)
see on pubmed
on Atopic Dermatitis
JAK-inhibitors in dermatology: current evidence and future applications.
Ciechanowicz P et al.
JAK-inhibitors in dermatology: current evidence and future applications.
J Dermatolog Treat.
2019 Nov , 30, (7):648-658.
The Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway is a ubiquitous intracellular signaling network. Selective JAK-inhibitors have anti-inflammatory properties and have been approved in many countries for the treatment of rheumatoid arthritis (tofacitinib, baricitinib) and myelofibrosis or polycythemia vera (ruxolitinib). The aim of the publication was to summarize and critically analyze the efficacy and safety of JAK-inhibitors in skin diseases, such (...)
see on pubmed
A case of infective endocarditis associated with atopic dermatitis perioperatively treated with dupilumab.
J Dermatolog Treat.
2019 Nov , 30, (7):674-676.
Several case reports and reviews support a relationship between atopic dermatitis (AD) and infective endocarditis (IE). Here, we present a case of severe AD suspected of causing IE. A 21-year-old man with severe AD was admitted to our hospital due to unidentified fever, syncope, and headache. He was diagnosed with IE with cerebral embolism and mitral regurgitation. Before elective cardiac surgery, he was subcutaneously administered dupilumab for 2 months to control AD. Dupilumab improved (...)
see on pubmed
Effect of cinnamamides on atopic dermatitis through regulation of IL-4 in CD4 cells.
Choi EJ et al.
Effect of cinnamamides on atopic dermatitis through regulation of IL-4 in CD4 cells.
J Enzyme Inhib Med Chem.
2019 Dec , 34, (1):613-619.
This study aimed to evaluate the effects of cinnamamides on atopic dermatitis (AD) and the mechanisms underlying these effects. To this end, the actions of two cinnamamides, (E)-3-(4-hydroxyphenyl)-N-phenylethyl acrylamide (NCT) and N-trans-coumaroyltyramine (NCPA), were determined on AD by orally administering them to mice. Oral administration of the cinnamamides ameliorated the increase in epidermal and dermal thickness as well as mast cell infiltration. Cinnamamides suppressed serum (...)
see on pubmed
